Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.66 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.63 |
| ▸ | FAP | Q12884 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649501 | 1.00 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL297708 | 1.00 | DPP4 (0.66) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL16710010 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL16578291 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6824150 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6824148 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL27616477 | 0.98 | DPP4 (0.64) | DPP4DPP8DPP9DPP7FAP | |
| Trifluoroacetic Acid SCHEMBL6923872 | 0.89 | DPP4 (0.67) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3628073 | 0.84 | DPP4 (0.60) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL5966905 | 0.84 | DPP4 (0.60) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1784220-B | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG | 2011-08-03 | — | — | CN | claimed |
| CN-101837127-A | The application of glutaminyl and glutamate cyclase effector | PROBIODRUG AG | 2010-09-22 | — | — | CN | claimed |
| CN-101365476-A | Combination of a DPP-IV inhibitor and a gastrin compound | WARATAH PHARMACEUTICALS INC (CA) | 2009-02-11 | — | — | CN | claimed |
| CN-1321682-C | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents | PROBIODRUG AG (DE) | 2007-06-20 | — | — | CN | claimed |
| CN-1582149-A | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROBIODRUG AG (DE) | 2005-02-16 | — | — | CN | claimed |
| CN-1443068-A | Combinations of depepotidyl peptidase IV inhibitors and other antidiabetic agents for treatment of diabete mellitus | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | CN | claimed |
| CN-1420797-A | Methods for improving islet signaling in diabetes and for its prevention | PROBIODRUG GES FUER ARZNEIM (DE) | 2003-05-28 | — | — | CN | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-3023095-B2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2023-11-08 | — | — | EP | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| EP-1215207-A2 | Salts of isoleucyl-thiazolidine and -pyrrolidine and their use as dipeptidylpeptidase inhibitors | Probiodrug AG (DE) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214936-A2 | Use of thiazolidin- or pyrrolidin-derivatives of aminoacids as antihyperglycemic agents | Probiodrug AG (DE) | 2002-06-19 | — | — | EP | disclosed |
| US-20010025023-A1 | Inhibition of beta cell degeneration | NOVO NORDISK A/S (DK) | 2001-09-27 | — | — | US | disclosed |
| WO-2001062266-A2 | USE OF DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001040180-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES AND THEIR USE AS ANTIDIABETIC AGENTS | FERRING BV (NL) | 2001-06-07 | — | — | WO | disclosed |
| EP-1082314-A1 | NEW DIPEPTIDYL PEPTIDASE IV EFFECTORS | Probiodrug Gesellschaft für Arzneimittelforschung mbH (DE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061431-A1 | NEW DIPEPTIDYL PEPTIDASE IV EFFECTORS | Probiodrug Gesellschaft für Arzneimittelforschung mbH (DE) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | DPP4 798/4885DPP8 521/4885DPP9 617/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | DPP4 935/4885DPP8 705/4885DPP9 414/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | DPP4 911/4885DPP8 697/4885DPP9 449/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | DPP4 747/4885DPP8 825/4885DPP9 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.